CG OncologyCGON
CGON
About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Employees: 61
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
531% more call options, than puts
Call options by funds: $6.49M | Put options by funds: $1.03M
119% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 27
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
16% more funds holding
Funds holding: 121 [Q3] → 140 (+19) [Q4]
10.54% more ownership
Funds ownership: 77.84% [Q3] → 88.38% (+10.54%) [Q4]
9% more funds holding in top 10
Funds holding in top 10: 11 [Q3] → 12 (+1) [Q4]
3% less capital invested
Capital invested by funds: $1.96B [Q3] → $1.9B (-$68.3M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
115%
upside
Avg. target
$68
167%
upside
High target
$75
193%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Jeffrey Hung 29% 1-year accuracy 8 / 28 met price target | 115%upside $55 | Overweight Assumed | 7 Mar 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 112 / 352 met price target | 193%upside $75 | Buy Reiterated | 13 Jan 2025 |
HC Wainwright & Co. Andres Maldonado 21% 1-year accuracy 10 / 48 met price target | 193%upside $75 | Buy Reiterated | 10 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET.
Positive
Zacks Investment Research
1 month ago
Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?
The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
2 months ago
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the closing of its public offering of 9,200,000 shares of its common stock, 8,500,000 of which were offered by CG Oncology, which includes the exercise in full by the underwriters of their option to purchase 1,200,000 additional shares, and 700,000 of which were offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share.
Positive
Seeking Alpha
2 months ago
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
CG Oncology, Inc. reported positive phase 3 BOND-003 results for Cretostimogene in treating BCG-unresponsive NMIBC, presented at the SUO 25th Annual Meeting. The company aims to use Cretostimogene as a backbone therapy for NMIBC and has shown increased response rates when combined with KEYTRUDA. CG Oncology plans to expand Cretostimogene's use to intermediate-risk NMIBC patients with the phase 3 PIVOT-006 trial, targeting enrollment completion in 1H 2026.
Neutral
GlobeNewsWire
2 months ago
CG Oncology Announces Pricing of Public Offering
IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its public offering of 8,000,000 shares of its common stock, 7,300,000 of which are being offered by CG Oncology and 700,000 of which are being offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share.
Neutral
GlobeNewsWire
3 months ago
CG Oncology Announces Proposed Public Offering
IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 7,300,000 shares of its common stock.
Positive
Reuters
3 months ago
Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer
An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer respond to current therapies, researchers reported on Thursday at the Society of Urologic Oncology meeting in Dallas.
Neutral
GlobeNewsWire
3 months ago
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
SCHAUMBURG, Ill. and IRVINE, Calif.
Neutral
GlobeNewsWire
3 months ago
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle
Positive
MarketBeat
4 months ago
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
Charts implemented using Lightweight Charts™